KT-095

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameKT-095

Drug Alias NameKT-095

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionT lymphocyte replacementsAnti-CD276

TargetsCD276 antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesNanjing Kati Medical Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesThe First People'S Hospital Of Lianyungang

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A